AI In Drug Development: Avoid The ‘Flashiness,’ And Simply Ask ‘Does It Fit?’ – US FDA’s ElZarrad

 
• By Kate Rawson
artificial intelligence
ElZarrad said the FDA may have to think of new approaches for AI transparency. • Source: Shutterstock

More from AI

More from Advanced Technologies